
[Claims]

[Claim 1]

A pharmaceutical composition comprising:

a compound represented by formula 1:

[Chemical Formula 1]



or a pharmaceutically acceptable salt or solvate thereof;

a binding agent; and

a dispersant.

[Claim 2]

The pharmaceutical composition of claim 1, wherein the binding agent comprises a binding agent selected from the group consisting of a cellulose binding agent, a povidone binding agent, a vinyl alcohol binding agent, and a thickening polysaccharide binding agent.

[Claim 3]

The pharmaceutical composition of claim 2, wherein

(i) the cellulose binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose, hypromellose, and methyl cellulose, or

(ii) the povidone binding agent comprises a binding agent selected from the group consisting of povidone and copovidone, or

(iii) the vinyl alcohol binding agent comprises a binding agent selected from the group consisting of polyvinyl alcohol and a polyvinyl alcohol-polyethylene glycol graft copolymer, or

(iv) the thickening polysaccharide binding agent comprises xanthan gum.

.

[Claim 4]

The pharmaceutical composition of any one of claims 1 to 3, wherein the dispersant is selected from the group consisting of an inorganic salt dispersant, an ether dispersant, a starch dispersant, a cellulose dispersant, and a fatty acid ester salt dispersant.

[Claim 5]

The pharmaceutical composition of claim 4, wherein

(i) the inorganic salt dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid and magnesium aluminometasilicate, or

(ii) the ether dispersant comprises polyethylene glycol 6000, or

(iii) the starch dispersant comprises corn starch, or

(iv) the cellulose dispersant comprises a dispersant selected from the group consisting of crystalline cellulose/carmellose sodium, carmellose, and carmellose calcium, or

(v) the fatty acid ester salt dispersant comprises sodium stearyl fumarate.

[Claim 6]

The pharmaceutical composition of claim 1, wherein:

(i) the binding agent comprises a cellulose binding agent, and

the dispersant comprises a dispersant selected from the group consisting of an inorganic salt dispersant, an ether dispersant, a starch dispersant, a cellulose dispersant, and a fatty acid ester salt dispersant, or

(ii) the binding agent comprises a cellulose binding agent, and

the dispersant comprises a dispersant selected from the group consisting of an inorganic salt dispersant, an ether dispersant, a starch dispersant, and a cellulose dispersant,

or

(iii) the binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose, hypromellose, and methyl cellulose, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid, polyethylene glycol 6000, corn starch, carmellose, crystalline cellulose/carmellose sodium, magnesium aluminometasilicate, sodium stearyl fumarate, and carmellose calcium, or

(iv) the binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose, hypromellose, and methyl cellulose, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid, polyethylene glycol 6000, corn starch, and carmellose, or

(v) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid, corn starch, carmellose, polyethylene glycol 6000, crystalline cellulose/carmellose sodium, magnesium aluminometasilicate, sodium stearyl fumarate, and carmellose calcium, or

(vi) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid, corn starch, and carmellose, or

(vii) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises light anhydrous silicic acid, or

(viii) the binding agent comprises hypromellose, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid and polyethylene glycol 6000, or

(ix) the binding agent comprises hypromellose, and

the dispersant comprises light anhydrous silicic acid, or

(x) the binding agent comprises methyl cellulose, and

the dispersant comprises light anhydrous silicic acid, or

(xi) the binding agent comprises a povidone binding agent, and

the dispersant comprises a dispersant selected from the group consisting of an inorganic salt dispersant, an ether dispersant, a starch dispersant, a cellulose dispersant, and a fatty acid ester salt dispersant, or

(xii) the binding agent comprises a povidone binding agent, and

the dispersant comprises a dispersant selected from the group consisting of an inorganic salt dispersant and a cellulose dispersant, or

(xiii) the binding agent comprises copovidone, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid and crystalline cellulose/carmellose sodium, or

(xiv) the binding agent comprises a cellulose binding agent, and

the dispersant comprises an inorganic salt dispersant.

[Claim 7]

The pharmaceutical composition of claim 6, wherein

the binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose, hypromellose, and methyl cellulose, and

the dispersant comprises a dispersant selected from the group consisting of light anhydrous silicic acid and magnesium aluminometasilicate.

[Claim 8]

The pharmaceutical composition of claim 7, wherein

the binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose, hypromellose, and methyl cellulose, and

the dispersant comprises light anhydrous silicic acid.

[Claim 9]

The pharmaceutical composition of claim 8, wherein

the binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose and hypromellose, and

the dispersant comprises light anhydrous silicic acid.

[Claim 10]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a cellulose binding agent, and

the dispersant comprises an ether dispersant, and/or

(ii) the binding agent comprises a binding agent selected from the group consisting of hydroxypropyl cellulose and hypromellose, and

the dispersant comprises polyethylene glycol 6000, and/or

(iii) the binding agent comprises hypromellose, and

the dispersant comprises polyethylene glycol 6000.

[Claim 11]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a cellulose binding agent, and

the dispersant comprises a starch dispersant, and/or

(ii) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises corn starch.

[Claim 12]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a cellulose binding agent, and

the dispersant comprises a cellulose dispersant, and/or

(ii) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises a dispersant selected from carmellose, crystalline cellulose/carmellose sodium, and carmellose calcium, and/or

(iii) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises a dispersant selected from crystalline cellulose/carmellose sodium and carmellose calcium, or

the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises carmellose.

[Claim 13]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a cellulose binding agent, and

the dispersant comprises a fatty acid ester salt dispersant, and/or

(ii) the binding agent comprises hydroxypropyl cellulose, and

the dispersant comprises sodium stearyl fumarate.

[Claim 14]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a povidone binding agent, and

the dispersant comprises a cellulose dispersant, and/or

(ii) the binding agent comprises copovidone, and

the dispersant comprises crystalline cellulose/carmellose sodium.

[Claim 15]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a povidone binding agent, and

the dispersant comprises an inorganic salt dispersant, and/or

(ii) the binding agent comprises a binding agent selected from the group consisting of copovidone, povidone (nominal K value: 29 to 32), and povidone (nominal K value: 17), and

the dispersant comprises light anhydrous silicic acid, and/or

[

(iii) the binding agent comprises a binding agent selected from the group consisting of copovidone and povidone (nominal K value: 29 to 32), and

the dispersant comprises light anhydrous silicic acid.

[Claim 16]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a vinyl alcohol binding agent,

and

the dispersant comprises an inorganic salt dispersant, and/or

(ii) the binding agent comprises a binding agent selected from the group consisting of polyvinyl alcohol and a polyvinyl alcohol/polyethylene glycol/graft copolymer, and

the dispersant comprises light anhydrous silicic acid, and/or

(iii) the binding agent comprises a polyvinyl alcohol/polyethylene glycol/graft copolymer, and

the dispersant comprises light anhydrous silicic acid.

[Claim 17]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a vinyl alcohol binding agent, and

the dispersant comprises a cellulose dispersant, and/or

(ii) the binding agent comprises a binding agent selected from the group consisting of polyvinyl alcohol and a polyvinyl alcohol/polyethylene glycol/graft copolymer, and

the dispersant comprises crystalline cellulose/carmellose sodium.

[Claim 18]

The pharmaceutical composition of claim 1, wherein

(i) the binding agent comprises a thickening polysaccharide binding agent, and

the dispersant comprises an inorganic salt dispersant, and/or

(ii) the binding agent comprises xanthan gum, and

the dispersant comprises light anhydrous silicic acid.

[Claim 19]

The pharmaceutical composition of any one of claims 1 to 18, wherein the pharmaceutical composition comprises a suspending agent, optionallywherein the suspending agent comprises a carboxyvinyl polymer.

[Claim 20]

The pharmaceutical composition of any one of claims 1 to 19, wherein the pharmaceutical composition comprises a sweetener, optionallywherein the sweetener comprises sucralose.

[Claim 21]

The pharmaceutical composition of any one of claims 1 to 20, wherein the pharmaceutical composition comprises 1 mg to 1000 mg of binding agent with respect to 1000 mg of a compound represented by formula I or a pharmaceutically acceptable salt or solvate thereof.

[Claim 22]

The pharmaceutical composition of any one of claims 1 to 21, wherein the pharmaceutical composition comprises a dispersant at 0.01 to 10% by weight with respect to the weight of the entire composition.

[Claim 23]

The pharmaceutical composition of any one of claims 1 to 22, wherein the pharmaceutical composition comprises 1 mg to 1000 mg of suspending agent with respect to 1000 mg of a compound represented by formula I or a pharmaceutically acceptable salt or solvate thereof.

[Claim 24]

The pharmaceutical composition of any one of claims 1 to 23, wherein the pharmaceutical composition comprises 1 mg to 1000 mg of sweetener with respect to 1000 mg of a compound represented by formula I or a pharmaceutically acceptable salt or solvate thereof.

[Claim 25]

A granule for suspension for the manufacture of a pharmaceutical composition, comprising the pharmaceutical composition of any one of claims 1 to 24.

[Claim 26]

The granule for suspension of claim 25, which is a granule for suspension for the preparation of a suspension.

[Claim 27]

A granule for suspension for the manufacture of a

pharmaceutical composition, wherein the granule for suspension is the pharmaceutical composition of any one of claims 1 to 24.

[Claim 28]

The granule for suspension of claim 27, which is a granule for suspension for the preparation of a suspension.

[Claim 29]

The pharmaceutical composition of any one of claims 1 to 28, which is a granule for suspension for the manufacture of a pharmaceutical composition.

[Claim 30]

The pharmaceutical composition of claim 29, which is a granule for suspension for the preparation of a suspension.

[Claim 31]

A suspension comprising the pharmaceutical composition of any one of claims 1 to 24, which is a granule for suspension for the manufacture of a pharmaceutical composition.

[Claim 32]

The pharmaceutical composition of any one of claims 1 to 24, which is in a suspended state.